Daily News

Daily News

Baicalein alleviates erectile dysfunction associated with induced type I diabetes in experimental research

NewsRx Diabetes Daily

2020 JUL 09 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx Diabetes Daily -- Fresh data on Nutritional and Metabolic Diseases and Conditions - Type 1 Diabetes are presented in a new report. According to news reporting originating from Hubei, People’s Republic of China, by NewsRx correspondents, research stated, “Management of diabetes mellitus induced-erectile dysfunction (DMED) is challenging because of its poor responses to phosphodiesterase type 5 inhibitors. Increasingly important roles of 12-lipoxygenase (12-LOX) have been proven in diabetes mellitus.”

Financial support for this research came from National Natural Science Foundation of China.

Our news editors obtained a quote from the research from the Huazhong University of Science and Technology, “To investigate 12-LOX activity and therapeutic effect of its inhibitor, baicalein (BE), on DMED. Intraperitoneal streptozotocin injection was used to induce type I DM, and an apomorphine test was used to evaluate erectile function. In experiment A, we assessed 12-LOX expression alteration in the corpus cavernosum (CC) of rats with DMED of different levels of severity. In experiment B, rats with DMED were intraperitoneally injected with BE for 4 weeks, and control rats were injected with vehicles. The erectile function was tested by cavernous nerve stimulation before penile tissue was harvested. We performed Western blot, immunohistochemistry, immunofluorescence, Masson trichrome staining, and enzyme-linked immunosorbent assays to measure related proteins in CC. The main outcome measures included rectile response, histologic examination, and expression alteration of related proteins. 12-LOX upregulation was associated with the progression of type I DMED. After 4 weeks treatment, compared with the DMED group, the DMED + BE group showed better erectile responses to cavernous nerve stimulation. In the DMED + BE group, significantly enhanced endothelial nitric oxide synthase/nitric oxide/cyclic guanosine monophosphate pathway, reduced 12-LOX expression, and inhibited p38 mitogen-activated protein kinase/arginase II/L-arginine pathway were showed in CC relative to the DMED group. In addition, overactivated oxidative stress and fibrosis in the DMED group were both partially ameliorated in the DMED + BE group. BE may be considered as an effective therapy for DMED, but needs to be verified in future human investigations. The role of 12-LOX and its inhibitor, BE, is firstly demonstrated in rats with type I DMED. However, the experimental data are derived from animal models with without evidences from cellular-based experiments. 12-LOX might serve as an important factor in the pathogenesis of type I DMED. BE alleviated erectile dysfunction in rats with type I DMED probably by inhibiting 12-LOX expression, ameliorating endothelial nitric oxide synthase dysfunction, as well as suppressing oxidative stress and fibrosis. Chen Y, Zhou B, Yu Z, et al.”

According to the news editors, the research concluded: “Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis. J Sex Med.”

For more information on this research see: Baicalein Alleviates Erectile Dysfunction Associated With Streptozotocin-Induced Type I Diabetes by Ameliorating Endothelial Nitric Oxide Synthase Dysfunction, Inhibiting Oxidative Stress and Fibrosis. The Journal of Sexual Medicine, 2020;():. The Journal of Sexual Medicine can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

The news editors report that additional information may be obtained by contacting Bingyan Zhou, Pediatric Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China. Additional authors for this research include Yinwei Chen, Zhe Yu, Penghui Yuan, Taotao Sun, Jianan Gong, Yan Zhang, Tao Wang, Shaogang Wang, Kang Liu and JiHong Liu.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1016/j.jsxm.2020.04.390. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the The Journal of Sexual Medicine is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)